血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究*

doi:10.3969/j.issn.1672-5069.2024.02.021

摘要/Abstract

摘要： 目的探讨应用血清氨基末端B型尿钠肽前体(NT-ProBNP)和肌钙蛋白Ⅰ(TnI)联合心电图(EKG)检查诊断肝硬化性心肌病(CCM)的价值。方法 2020年1月～2023年3月我院收治的肝硬化患者93例和健康体检者49例, 均接受EKG检查, 采用化学发光免疫法检测血清TnI水平, 采用ELISA法检测血清NT-ProBNP水平。应用受试者工作特征曲线(ROC)并计算曲线下面积(AUC)评估指标的诊断效能。结果本组肝硬化患者存在CCM者51例(NYHAⅠ级18例, Ⅱ级20例和Ⅲ级13例);CCM组血清NT-ProBNP和TnI水平分别为(41.5±7.9)pmol/L和(0.6±0.2)μg/mL, 显著高于肝硬化组【分别为(28.9±5.2)pmol/L和(0.3±0.1)μg/mL, P<0.05】或健康人【分别为(8.3±1.6)pmol/L和(0.1±0.1)μg/mL, P<0.05】;CCM组心电图异常率为98.0%, 显著高于肝硬化组的71.4%或健康人组的2.0%(P<0.05);CCM Ⅲ级患者血清NT-ProBNP和TnI水平分别为(48.3±8.5)pmol/L和(0.8±0.2)pmol/L, 显著高于Ⅱ级患者【分别为(42.1±7.8)pmol/L和(0.6±0.1)pmol/L, P<0.05】或Ⅰ级患者【分别为(35.9±7.9)pmol/L和(0.5±0.1)pmol/L, P<0.05】;分别以血清NT-ProBNP水平=40.4 pmol/L和TnI水平=0.5μg/mL为截断点, 联合心电图检查异常诊断CCM的AUC=0.923, 其诊断的灵敏度和特异度分别为94.1%和78.6%, 显著优于各指标单独诊断(P<0.05)。结论检测血清NT-ProBNP和TnI水平联合心电图检查可以帮助临床医生早期诊断肝硬化患者并发CCM, 值得深入研究。

关键词: 肝硬化性心肌病, 氨基末端B型尿钠肽前体, 肌钙蛋白Ⅰ, 心电图, 诊断

Abstract: Objective The aim of this study was to explore serum N-terminal pro-brain natriuretic peptide (NT-ProBNP) and troponin I (TnI) level changes in patients with liver cirrhosis for early diagnosis of cirrhotic cardiomyopathy (CCM). Methods 93 patients with liver cirrhosis and 49 healthy persons at physical examination were enrolled in our hospital between January 2020 and March 2023, and all underwent electrocardiography (EKG). Serum TnI level was detected by chemiluminescence immunoassay and serum NT-ProBNP level was measured by ELISA. The diagnostic performance was evaluated by the area under the receiver operating characteristic curve (AUROC) analysis. Results Out of our series, the CCM was found in 51 cases, including NYHA classⅠ in 18 cases, class Ⅱ in 20 cases and class Ⅲ in 13 cases based on cardiac Doppler ultrasonography; serum NT-ProBNP and TnI levels in patients with CCM were (41.5±7.9)pmol/L and (0.6±0.2)μg/mL, significantly higher than in cirrhotics without CCM or in healthy individuals; the abnormal EKG manifestation in patients with CCM accounted for 98.0%, much higher than 71.4% in patients with liver cirrhosis or 2.0%(P<0.05) in healthy persons; serum NT-ProBNP and TnI levels in patients with CCM class Ⅲ were (48.3±8.5)pmol/L and (0.8±0.2)pmol/L, significantly higher than in patients with CCM class Ⅱ or in patients with CCM class Ⅰ; the AUC was 0.923, with the sensitivities of 94.1% and the specificities of 78.6% when serum NT-ProBNP level equal to 40.4 pmol/L and serum TnI level equal to 0.5μg/mL were set as the cut-off-value, and with abnormal EKG combination in predicting CCM, much superior to any of the parameters did alone (P<0.05). Conclusion The elevated serum NT-ProBNP and TnI levels in patients with decompensated liver cirrhosis might hint the existence of CCM, which occurs early before abnormal EKG manifestations loom.

Key words: Cirrhotic cardiomyopathy, N-terminal pro-brain natriuretic peptide, Troponin I, Electrocardiogram, Diagnosis

朱春芬, 任春霖, 郭霞. 血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 242-245.

Zhu Chunfen, Ren Chunlin, Guo Xia. Elevated serum NT-ProBNP and TnI levels occurs before abnormal electrocardiogram manifestations in patients with cirrhotic cardiomyopathy[J]. Journal of Practical Hepatology, 2024, 27(2): 242-245.

参考文献

[1] Kouvari M, Tsiampalis T, Chrysohoou C,et al.The quality of plant-based dietary patterns affects the ten-year cardiovascular disease risk of participants with non-alcoholic fatty liver disease: highlights from a population-based cohort study.Eur Heart J, 2021, 42(1):7-10.
[2] Zhang M, Ma N, Zang T,et al.Clinical value of n-terminal pro-brain natriuretic peptide (NT-proBNP) levels in the diagnosis of heart failure in elderly Population.Basic Clin Pharmacol Toxicol, 2021, 128(S3):71-72.
[3] Bockstahler M, Salbach C, Müller AM,et al.LNA oligonucleotide mediates an anti-inflammatory effect in autoimmune myocarditis via targeting lactate dehydrogenase B.Immunology, 2022, 165(2):158-170.
[4] Bugrov A, Roitman A, Beganskaya L, et al.Procalcitonin (PCT), C-reactive protein (CRP), cardiac troponin I (TNI) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and prognosis in infective endocarditis. Clinica Chimica Acta, 2019, 495(6):S175
[5] 中华医学会肝病学分会.肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792.
[6] Dimitroglou Y, Aggeli C, Alexopoulou A, et al.Left atrial reservoir strain may be a load independent index of diastolic dysfunction in liver cirrhosis patients. Eur Heart J Cardiovasc Imaging, 2022, 23(1):9-10.
[7] Izzy M, Soldatova A, Sun X, et al. Cirrhotic cardiomyopathy predicts post-transplant cardiovascular disease: revelations of the new diagnostic criteria. Liver Transpl, 2021,27(6):876-886.
[8] 汪菁峰,马婧嶔,罗剑钧,等.肝硬化患者经颈静脉肝内门体分流术对血流动力学的影响.中华内科杂志,2020,59(9):700-705.
[9] Hussain A, Sun W, Deswal A, et al.Association of NT-ProBNP, blood pressure, and cardiovascular events. J Am Coll Cardiol, 2021, 77(5):559-571.
[10] Bender M, Stein M, Schoof B, et al.Troponin I as an early biomarker of cardiopulmonary parameters during the first 24 h of intensive care unit treatment in isolated traumatic brain injury patients.Injury, 2020,51(5):1189-1195.
[11] 赵晗,刘文娴,任燕龙,等.成人急性心肌炎住院期间发生不良心脏事件影响因素分析.中华急诊医学杂志,2019,28(7):841-845.
[12] 雷菊,尹立雪,胥桐,等.肝硬化左心室机械力学功能不全的分层应变定量研究.中华超声影像学杂志,2021,30(12):1026-1032.
[13] Izzy M, Lin G, Watt KD.Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link? J Hepatol, 2021,75(4):992-993.
[14] Pezzato A, Milandri A, Tortorici G, et al.Pragmatic electrocardiogram tracings in non-ischaemic dilated cardiomyopathy: diagnostic and prognostic role.Eur Heart J Suppl,2023,25(Suppl C):C162-C168.
[15] 霍会芹,巩晓红,李正宏.采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能.实用肝脏病杂志,2019,22(2):244-247.
[16] Kouvari M, Chrysohoou C, Skoumas J,et al.Liver steatosis, metabolically healthy obesity and ten-year cardiovascular disease risk: results from a population based cohort study. Eur Heart J, 2021, 42(1):2643.
[17] Olubamwo OO, Virtanen JK, Pihlajamaki J, et al.Fatty liver index as a predictor of increased risk of cardiometabolic disease: finding from the kuopio ischaemic heart disease risk factor study cohort.BMJ Open, 2019, 9(9):e031420.
[18] Izzy M, VanWagner LB, Lin G,et al.Redefining cirrhotic cardiomyopathy for the modern era. Hepatology, 2020,71(1):334-345.
[19] Scandinaro A, Haider M, Saef J, et al.Hematologic abnormalities as a marker of cirrhosis after fontan completion.Eur Heart J, 2021, 42(1):1885.
[20] Deffke PO, Westphal JG, Settmacher U, et al.Risk stratification and survival in patients after liver transplantation: the role of right heart function and dimension.Eur Heart J, 2021, 42(1):2796.7.

血清NT-ProBNP和TnI联合心电图检查早期诊断肝硬化性心肌病价值研究^*

Elevated serum NT-ProBNP and TnI levels occurs before abnormal electrocardiogram manifestations in patients with cirrhotic cardiomyopathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	徐京杭, 于岩岩, 徐小元. 肝硬化临床研究进展[J]. 实用肝脏病杂志, 2024, 27(2): 161-164.
[2]	郭萌, 郭琦, 张峰. 超声瞬时弹性成像检测受控衰减参数评估非酒精性脂肪性肝病患者肝脂肪变程度价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 189-192.
[3]	李敏, 张丽, 曾艾, 刘世裕. 2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化检出率及预测因素分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 193-197.
[4]	郑波, 哈丽达·夏尔甫哈孜, 谈理. 非酒精性脂肪性肝病患者血清HIF-1α、HMGB1和脂联素水平变化及其与颈动脉粥样硬化的关系研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 198-201.
[5]	童静, 张珂瓈, 李昌平. 非酒精性脂肪性肝炎患者血清前神经降压素和微小RNA-122水平变化及其诊断脂肪性肝炎的价值探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 202-205.
[6]	冯彦菲, 苏明华, 殷倩冰, 黎清梅, 苏土梅, 梁蘅恺, 韦璐, 黄建芳, 江建宁. 一组非肝硬化性门静脉高压症病因分析和诊断路径探讨^*[J]. 实用肝脏病杂志, 2024, 27(2): 246-250.
[7]	哈鹏, 苏晓晨, 付宾鹏. 三期增强CT扫描联合血清AFP和VEGF水平诊断肝细胞癌患者临床研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 251-254.
[8]	谢晶美, 刘浩, 李安, 李华, 陈苗苗, 郭宝琴, 石洋洋, 朱志敏, 郭晨光. 动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 255-258.
[9]	崔甜甜, 张海波, 陈莉莉. 能谱CT增强扫描参数鉴别诊断肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(2): 275-278.
[10]	魏野, 汪施妤, 葛高华, 井桂银. CT增强扫描与磁共振检查诊断肝血管瘤和肝细胞癌价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 279-282.
[11]	贾永利, 王鹏川, 郭伟, 孙东莹. 低频与高频超声联合诊断胆囊息肉样病变价值分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 307-310.
[12]	章正威, 夏德鑫, 朱宝林, 章应峰, 王翔, 张彤. 早期原发性胆囊癌增强磁共振和CT扫描征象分析^*[J]. 实用肝脏病杂志, 2024, 27(2): 311-313.
[13]	诸葛宇征. 重视内脏静脉血栓形成的诊断和管理^*[J]. 实用肝脏病杂志, 2024, 27(1): 1-2.
[14]	鲁文婷, 张峰. 非肝硬化门静脉系统血栓形成临床管理[J]. 实用肝脏病杂志, 2024, 27(1): 7-10.
[15]	李凯, 石波, 程序, 赵凯. 应用STE/STQ技术评估慢性乙型肝炎患者肝纤维化程度效能研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 20-23.